Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating fa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Cham, Jason, Zhang, Li, Kwek, Serena, Paciorek, Alan, He, Tao, Fong, Grant, Oh, David Y, Fong, Lawrence
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7223469/
https://ncbi.nlm.nih.gov/pubmed/32376721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000368
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky